Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 154.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -9.00K | -137.00K | -135.00K | -268.00K | -87.00K | -201.00K |
EBITDA | -33.23M | -25.52M | -19.85M | -19.20M | -14.19M | -9.96M |
Net Income | -29.55M | -25.65M | -18.35M | -19.68M | -14.27M | -10.00M |
Balance Sheet | ||||||
Total Assets | 35.83M | 35.35M | 55.22M | 71.86M | 70.36M | 8.41M |
Cash, Cash Equivalents and Short-Term Investments | 12.12M | 11.61M | 23.18M | 41.79M | 67.33M | 6.23M |
Total Debt | 1.25M | 1.56M | 2.15M | 1.68M | 1.53M | 473.00K |
Total Liabilities | 25.21M | 16.29M | 15.52M | 17.30M | 4.96M | 3.15M |
Stockholders Equity | 10.62M | 19.07M | 39.70M | 54.56M | 65.41M | 8.03M |
Cash Flow | ||||||
Free Cash Flow | -18.09M | -16.94M | -19.20M | -19.20M | -12.90M | -12.18M |
Operating Cash Flow | -18.07M | -16.94M | -19.00M | -19.08M | -12.89M | -12.17M |
Investing Cash Flow | -16.00K | -1.00K | -202.00K | -4.40M | -14.00K | -9.00K |
Financing Cash Flow | 13.61M | 5.50M | 625.00K | -1.93M | 74.00M | 3.36M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.83B | -0.18 | -40.10% | 2.29% | 21.46% | -2.03% | |
45 Neutral | $4.03M | ― | -154.46% | ― | ― | 61.74% | |
45 Neutral | $10.68M | ― | -146.46% | ― | ― | 24.30% | |
32 Underperform | $3.52M | ― | -350.08% | ― | ― | 99.74% | |
31 Underperform | $3.14M | ― | 367.65% | ― | ― | 89.24% | |
29 Underperform | $4.45M | ― | -99.96% | ― | ― | 44.00% | |
28 Underperform | $7.62M | ― | -49.58% | ― | ― | 67.95% |
On March 31, 2025, Theriva Biologics announced positive outcomes from a second Independent Data Monitoring Committee (IDMC) review of the VIRAGE Phase 2b clinical trial for VCN-01 in combination with chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC). The review found VCN-01 to be well tolerated with an adverse event profile consistent with previous trials, indicating the feasibility of repeated dosing. This development could guide the design of a potential Phase 3 trial, impacting the company’s future clinical strategies and regulatory discussions.